RASAL1 Antibody

Code CSB-PA912569
Size US$166
Order now
Image
  • The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA912569(RASAL1 Antibody) at dilution 1/20, on the right is treated with fusion protein. (Original magnification: ×200)
  • The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA912569(RASAL1 Antibody) at dilution 1/20, on the right is treated with fusion protein. (Original magnification: ×200)
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
GAP1 like protein antibody; MRASAL antibody; RAS GTPase activating protein like antibody; RAS protein activator like 1 (GAP1 like) antibody; RAS protein activator like 1 antibody; RASAL antibody; Rasal1 antibody; rasGAP activating like protein 1 antibody; RasGAP-activating-like protein 1 antibody; RASGAP1 LIKE antibody; RASL1_HUMAN antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse
Immunogen
Fusion protein of Human RASAL1
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,IHC
Recommended Dilution
Application Recommended Dilution
ELISA 1:2000-1:5000
IHC 1:20-1:100
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Probable inhibitory regulator of the Ras-cyclic AMP pathway. Plays a role in dendrite formation by melanocytes.
Gene References into Functions
  1. Domain topology of human Rasal PMID: 28885980
  2. HIF1alpha and transforming growth factor (TGF)/SMAD signalling pathways synergistically regulate hypoxia-induced endothelial-to-mesenchymal transition through both DNMT3a-mediated hypermethylation of RASAL1 promoter and direct SNAIL induction. PMID: 27012941
  3. RASAL1 role in in sorafenib-resistance of liver cancer cells PMID: 27878301
  4. our study showed significantly longer overall survival times for oesophagogastric adenocarcinoma patients without RASAL1 expression PMID: 28011578
  5. DNA methylation, TGFbeta1 and RASAL1 appear to have an interacting relationship. PMID: 27124111
  6. Report a new subtype of high-grade mandibular osteosarcoma with RASAL1/MDM2 amplification. PMID: 26997440
  7. These findings suggest that Ebp1 suppressed thyroid cancer cell lines by upregulating RASRAL expression. PMID: 26008146
  8. large chromosome 12 rearrangement, spanning MDM2 and RASAL1, is the first recurrent molecular abnormality to be reported in juvenile ossifying fibroma PMID: 24925056
  9. Loss of RASAL1 expression is associated with gastric carcinogenesis. PMID: 25735335
  10. Transcriptional suppression of RASAL1 through aberrant promoter methylation contributes to endothelial-mesenchymal transition and ultimately to progression of cardiac fibrosis. PMID: 25616414
  11. Promoter hypermethylation of the RASAL1 gene was detected in MKN-28, SGC-790l and BGC-823 cancer cells. PMID: 24377515
  12. It is a tumor suppressor gene which influences the proliferation and invasion of gastric cancer by regulating RAS/ERK signaling pathway. PMID: 24531877
  13. Germline RASAL1 alterations are uncommon in patients with Cowden syndrome but may not be infrequent in patients with apparently sporadic follicular-variant papillary thyroid cancer. PMID: 24712574
  14. We identified RASAL1 as a major tumor suppressor gene that is frequently inactivated by hypermethylation and mutations, providing a new alternative genetic background for thyroid cancer, particularly FTC and ATC. PMID: 24136889
  15. Hypermethylations of RASAL1 and KLOTHO is associated with renal dysfunction in a Chinese population environmentally exposed to cadmium PMID: 23665422
  16. decreased RASAL1 expression is a characteristic of gastric cancer and regulated by epigenetic mechanisms PMID: 22825043
  17. Ras GTPase activating (RasGAP) activity of the dual specificity GAP protein Rasal requires colocalization and C2 domain binding to lipid membranes. PMID: 23251034
  18. Reduced expression of RAS protein activator like-1 is associated with gastric cancer. PMID: 20473946
  19. Galpha and Gbeta gamma require distinct Src-dependent pathways for its activation PMID: 12221082
  20. RASAL preservs of Ca2+ frequency information PMID: 16009725
  21. RASAL constitutes a tumor suppressor gene and therefore further emphasized the importance of Ca(2+) in the regulation of Ras signaling and has established that deregulation of this pathway is an important step in Ras-mediated tumorigenesis PMID: 17640920
  22. Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. PMID: 18992247

Show More

Hide All

Tissue Specificity
Highly expressed in thyroid and adrenal medulla, lower expression in brain, spinal cord and trachea. Expressed in melanocytes.
Database Links

HGNC: 9873

OMIM: 604118

KEGG: hsa:8437

STRING: 9606.ENSP00000450244

UniGene: Hs.528693

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*